Boehringer Ingelheim and Gubra begin Phase I trial of drug candidate for obesity
The trial has enrolled an estimated 124 participants and is expected to be completed in the second half of next year.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
